Portfolio company
Avant Genomics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops an automated platform for liquid biopsy sample preparation to assist clinical laboratories in cancer detection and monitoring.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Epiliquid
This company develops blood-based liquid biopsy tests for early cancer detection and monitoring, serving clinical laboratories and medical practitioners.
Vortex
This company produces automated liquid biopsy systems that isolate circulating tumour cells from blood samples for researchers and clinicians in the oncology sector.
Guardant
The company develops blood-based liquid biopsy tests for cancer screening and monitoring for patients and healthcare providers.
Oncoliq
This company develops liquid biopsy tests using molecular biology and machine learning for early cancer detection in clinical and screening settings.
Infiniplex
This company develops liquid biopsy solutions using blood tests to monitor genetic biomarkers for cancer screening and precision oncology decisions for healthcare providers.
Foresight Diagnostics
This company develops liquid biopsy tests to detect minimal residual disease in cancer patients for biopharmaceutical companies and healthcare providers.
LiquidCell Dx
This company develops blood-based liquid biopsy tests for tumor microenvironment profiling to help pharmaceutical companies and clinical partners predict cancer therapy responses.
Genomill Health
Genomill Health develops targeted sequencing technology for liquid biopsies to assist clinical laboratories and pharmaceutical companies with precision cancer diagnostics.